Skip to content

Flaxseed, Aromatase Inhibitors and Breast Tumor Characteristics

Flaxseed vs. Aromatase Inhibitors: Breast Tumor Characteristics and Prognosis

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00612560
Acronym
FABrC
Enrollment
28
Registered
2008-02-11
Start date
2007-11-30
Completion date
2014-04-30
Last updated
2017-10-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Keywords

breast neoplasms, phytoestrogens, tumor characteristics, proliferation, apoptosis, estrogen receptor, HER2

Brief summary

The proposed study plans to examine the effect of flaxseed consumption, a phytoestrogen rich food, compared to aromatase inhibitors as a complementary approach to treating estrogen receptor positive breast cancer, as well as the effect of combined flaxseed and aromatase inhibitor therapy on breast cancer treatment. Because of the increasing use of both complementary and alternative approaches to treatment, and the use of aromatase inhibitors in the treatment of breast cancer, the proposed study has potential to provide important clinical information about the effect of foods high in phytoestrogens on a common endocrine therapy used in breast cancer.

Detailed description

Although the 10 year survival rate for women with early stage breast cancer is very good, distant recurrence is still a serious concern, especially for estrogen receptor positive women. Consequently, breast cancer survivors are interested in therapies that might improve their recurrence free survival (RFS). Used in postmenopausal women, aromatase inhibitors (AI) block the peripheral conversion of androgens to estrogen, effectively lowering the estradiol available to promote breast tumor proliferation. However, use of AIs is associated with hot flashes, joint pain, bone loss, and an increase in cardiac events. Furthermore, many breast tumors eventually develop resistance to hormonal treatments. Complementary and alternative medicines (CAMs) are widely used by cancer survivors in an attempt to reduce disease recurrence with fewer side effects and potential health benefits, and use is particularly prevalent among breast cancer survivors. Flaxseed (FS) is a commonly available food often consumed as a dietary supplement and is the richest food source of lignans, a phytoestrogen. In experimental models, flaxseed consumption has been shown to exhibit a number of activities that suggest a potential benefit of flaxseed in the adjuvant setting. However, the majority of human studies investigating the biologic effects of flaxseed have involved healthy women. There is a paucity of clinical data regarding the efficacy and safety of use of flaxseed among women with breast cancer, especially among those receiving AIs. Because the phytoestrogens in flaxseed can influence many of the same biologic pathways affected by hormonal agents, diet-drug interactions are possible. Additionally, it is possible flaxseed could act through growth and signaling pathways, modifying the development of endocrine resistance. Potential synergistic or antagonistic effects between flaxseed and antiestrogens are of particular interest given the increasing use of AIs to treat postmenopausal women with hormone responsive disease. We propose to conduct a pilot 2x2 factorial randomized intervention study between tumor biopsy and resection, in postmenopausal women diagnosed with ER positive breast cancer, to assess the effects of flaxseed and AI on a number of steroid hormone and tumor-related characteristics associated with long-term survival, and to investigate the potential interaction between flaxseed and AI on tumor expression of Ki-67, caspase, ERα, ERβ, PgR, HER2, IGF1, IGFIR. The pre-surgical setting offers a unique opportunity to rapidly obtain information on intervention related effects on growth factor and signaling pathways related to tumor characteristics in a short time period without the interference of other treatments. We hypothesize that both flaxseed and AI interventions will independently favorably affect growth factor and signaling pathway protein expression resulting in reduced tumor proliferation and increased apoptosis. We further hypothesize that these improvements will be reflected in improved recurrence scores as estimated by the Mammostrat antibody panel (Applied Genomics Incorporated). The proposed study will provide important clinical data for future dietary intervention studies involving phytoestrogen lignans from flaxseed.

Interventions

DRUGAnastrozole

1 mg per day

DIETARY_SUPPLEMENTflaxseed

25 g per day ground

DRUGPlacebo

Placebo pill 1 per day

Sponsors

National Center for Complementary and Integrative Health (NCCIH)
CollaboratorNIH
AstraZeneca
CollaboratorINDUSTRY
Roswell Park Cancer Institute
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
FACTORIAL
Primary purpose
BASIC_SCIENCE
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

* Age ≥ 18 and ≤ 85 years * Postmenopausal status defined as: no menstrual cycle in the past 12 months hysterectomy with bilateral oophorectomy hysterectomy with intact ovaries if age \> 55 years * Newly diagnosed with incident, primary, invasive, estrogen receptor positive clinical stage II or lower breast cancer * ECOG performance status of 1 or less * Willingness to comply with study guidelines and procedures * Willingness and ability to provide informed consent * Usual consumption of soy no more than 1 time per week and willingness to avoid whole soy foods or concentrated soy sources (soy milk, tofu, substitute meat products, meal replacement bars) during the intervention period * Willingness to avoid herbal and dietary supplements (not including vitamins), aspirin, and ibuprofen during the intervention period * No competing neoadjuvant or chemotherapy treatment * Time between pre-surgical visit and surgery must be at least 2 weeks * No chemotherapy in the past 12 months

Exclusion criteria

* Inability to read and write English * Previous invasive breast cancer * Insulin dependent Type I or II diabetes diagnosed by physician * History of coagulopathy, thrombocytopenia, or bleeding disorder * Current (past 30 days) regular (at least once per week) use of reproductive hormone therapy, Tamoxifen, aromatase inhibitors, or other estrogen inhibitors, flaxseed, or antibiotics * Current chemotherapy or neoadjuvant chemotherapy * Allergies to flaxseed, nuts, or other seeds * Renal dysfunction defined as creatinine \> 1.5 mg/dl * History of Crohns' disease, ulcerative colitis, irritable bowel syndrome, celiac sprue, or other malabsorption syndrome, diverticulitis, diverticulosis, or other bowel diagnosis which, in the opinion of the breast surgeon, would contraindicate large doses of dietary fiber or would impair nutrient absorption * Current, regular (more than once weekly) use of prescription blood-thinning agents including coumadin, heparin and heparin related drugs, clopidogrel bisulfate

Design outcomes

Primary

MeasureTime frameDescription
Expression of Estrogen Receptor (ER-beta)Biopsy/Week 1 and Surgical Resection/Week 2Mean percentage of cells expressing estrogen receptor (ER-beta)
Progesterone Receptor (PR) ExpressionBiopsy/Week 1 and Surgical Resection/Week 2Mean percentage of cells expressing PR
Human Epidermal Growth Factor Receptor 2 (Her2) ExpressionBiopsy/Week 1 and Surgical Resection/Week 2Mean percentage of cells expressing human epidermal growth factor receptor 2 (Her2)

Secondary

MeasureTime frameDescription
Growth Hormone Serum Levels IGF-1Biopsy/Week 1 and Surgical Resection/Week 2Mean serum level IGF-1(pg/ml)

Countries

United States

Participant flow

Participants by arm

ArmCount
Arm A - Flaxseed & Active Anastrazole
25 mg flaxseed per day and 1 mg anastrozole pill per day Anastrozole: 1 mg per day flaxseed: 25 g per day ground
7
Arm B - Flaxseed
Flaxseed 25 mg per day and 1 placebo pill per day flaxseed: 25 g per day ground
7
Arm C - Anastrozole
Anastrozole 1 mg pill per day Anastrozole: 1 mg per day
8
Arm D - Placebo
Placebo pill 1 per day Placebo: Placebo pill 1 per day
6
Total28

Baseline characteristics

CharacteristicArm A - Flaxseed & Active AnastrazoleArm B - FlaxseedArm C - AnastrozoleArm D - PlaceboTotal
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
4 Participants1 Participants4 Participants3 Participants12 Participants
Age, Categorical
Between 18 and 65 years
3 Participants6 Participants4 Participants3 Participants16 Participants
Age, Continuous63 years
STANDARD_DEVIATION 8.5
58 years
STANDARD_DEVIATION 7.5
65 years
STANDARD_DEVIATION 6.6
64 years
STANDARD_DEVIATION 7.6
62 years
STANDARD_DEVIATION 7.6
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
Asian
0 Participants0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
Black or African American
0 Participants1 Participants0 Participants0 Participants1 Participants
Race (NIH/OMB)
More than one race
0 Participants0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
White
7 Participants6 Participants8 Participants6 Participants27 Participants
Sex: Female, Male
Female
7 Participants7 Participants8 Participants6 Participants28 Participants
Sex: Female, Male
Male
0 Participants0 Participants0 Participants0 Participants0 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
EG003
affected / at risk
deaths
Total, all-cause mortality
— / —— / —— / —— / —
other
Total, other adverse events
6 / 76 / 75 / 85 / 6
serious
Total, serious adverse events
0 / 70 / 71 / 80 / 6

Outcome results

Primary

Expression of Estrogen Receptor (ER-beta)

Mean percentage of cells expressing estrogen receptor (ER-beta)

Time frame: Biopsy/Week 1 and Surgical Resection/Week 2

Population: All treated and eligible patients with a large enough of a sample for analysis

ArmMeasureGroupValue (MEAN)Dispersion
Arm A - Flaxseed & Active AnastrazoleExpression of Estrogen Receptor (ER-beta)Biopsy67.1 percentage of cellsStandard Deviation 17
Arm A - Flaxseed & Active AnastrazoleExpression of Estrogen Receptor (ER-beta)Surgical resection45.7 percentage of cellsStandard Deviation 28.8
Arm B - FlaxseedExpression of Estrogen Receptor (ER-beta)Surgical resection56.7 percentage of cellsStandard Deviation 23.4
Arm B - FlaxseedExpression of Estrogen Receptor (ER-beta)Biopsy63.3 percentage of cellsStandard Deviation 10.3
Arm C - AnastrozoleExpression of Estrogen Receptor (ER-beta)Biopsy45.0 percentage of cellsStandard Deviation 23.8
Arm C - AnastrozoleExpression of Estrogen Receptor (ER-beta)Surgical resection46.7 percentage of cellsStandard Deviation 32.1
Arm D - PlaceboExpression of Estrogen Receptor (ER-beta)Biopsy62.0 percentage of cellsStandard Deviation 13
Arm D - PlaceboExpression of Estrogen Receptor (ER-beta)Surgical resection70 percentage of cellsStandard Deviation 30.9
Primary

Human Epidermal Growth Factor Receptor 2 (Her2) Expression

Mean percentage of cells expressing human epidermal growth factor receptor 2 (Her2)

Time frame: Biopsy/Week 1 and Surgical Resection/Week 2

Population: All treated and eligible patients with a large enough of a sample for analysis.

ArmMeasureGroupValue (MEAN)Dispersion
Arm A - Flaxseed & Active AnastrazoleHuman Epidermal Growth Factor Receptor 2 (Her2) ExpressionSurgical resection0 percentage of cellsStandard Deviation 0
Arm A - Flaxseed & Active AnastrazoleHuman Epidermal Growth Factor Receptor 2 (Her2) ExpressionBiopsy15 percentage of cellsStandard Deviation 7
Arm B - FlaxseedHuman Epidermal Growth Factor Receptor 2 (Her2) ExpressionSurgical resection17.5 percentage of cellsStandard Deviation 16.6
Arm B - FlaxseedHuman Epidermal Growth Factor Receptor 2 (Her2) ExpressionBiopsy40 percentage of cells
Arm C - AnastrozoleHuman Epidermal Growth Factor Receptor 2 (Her2) ExpressionSurgical resection17.5 percentage of cellsStandard Deviation 17.7
Arm D - PlaceboHuman Epidermal Growth Factor Receptor 2 (Her2) ExpressionBiopsy55 percentage of cellsStandard Deviation 63.6
Arm D - PlaceboHuman Epidermal Growth Factor Receptor 2 (Her2) ExpressionSurgical resection30 percentage of cells
Primary

Progesterone Receptor (PR) Expression

Mean percentage of cells expressing PR

Time frame: Biopsy/Week 1 and Surgical Resection/Week 2

Population: All treated and eligible patients with a large enough of a sample for analysis

ArmMeasureGroupValue (MEAN)Dispersion
Arm A - Flaxseed & Active AnastrazoleProgesterone Receptor (PR) ExpressionBiopsy4 percentage of cellsStandard Deviation 1.4
Arm A - Flaxseed & Active AnastrazoleProgesterone Receptor (PR) ExpressionSurgical resection4.5 percentage of cellsStandard Deviation 0.7
Arm B - FlaxseedProgesterone Receptor (PR) ExpressionSurgical resection2.4 percentage of cellsStandard Deviation 1.1
Arm B - FlaxseedProgesterone Receptor (PR) ExpressionBiopsy3.5 percentage of cellsStandard Deviation 0.7
Arm C - AnastrozoleProgesterone Receptor (PR) ExpressionBiopsy2 percentage of cells
Arm C - AnastrozoleProgesterone Receptor (PR) ExpressionSurgical resection1 percentage of cellsStandard Deviation 1.4
Arm D - PlaceboProgesterone Receptor (PR) ExpressionBiopsy4.7 percentage of cellsStandard Deviation 0.5
Arm D - PlaceboProgesterone Receptor (PR) ExpressionSurgical resection3.5 percentage of cellsStandard Deviation 2.1
Secondary

Growth Hormone Serum Levels IGF-1

Mean serum level IGF-1(pg/ml)

Time frame: Biopsy/Week 1 and Surgical Resection/Week 2

Population: All treated and eligible patients with a large enough of a sample for analysis

ArmMeasureGroupValue (MEAN)Dispersion
Arm A - Flaxseed & Active AnastrazoleGrowth Hormone Serum Levels IGF-1Biopsy887.7 pg/mlStandard Deviation 654.4
Arm A - Flaxseed & Active AnastrazoleGrowth Hormone Serum Levels IGF-1Surgical resection938.1 pg/mlStandard Deviation 652.9
Arm B - FlaxseedGrowth Hormone Serum Levels IGF-1Surgical resection980.5 pg/mlStandard Deviation 743.2
Arm B - FlaxseedGrowth Hormone Serum Levels IGF-1Biopsy1044.2 pg/mlStandard Deviation 700.4
Arm C - AnastrozoleGrowth Hormone Serum Levels IGF-1Biopsy959.1 pg/mlStandard Deviation 408.6
Arm C - AnastrozoleGrowth Hormone Serum Levels IGF-1Surgical resection819.8 pg/mlStandard Deviation 334.3
Arm D - PlaceboGrowth Hormone Serum Levels IGF-1Surgical resection880.1 pg/mlStandard Deviation 698
Arm D - PlaceboGrowth Hormone Serum Levels IGF-1Biopsy1008.3 pg/mlStandard Deviation 686.7

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026